A Phase 1b Open-label Study of Betalutin in Combination With Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (Archer-1)
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms ARCHER-1
- Sponsors Nordic Nanovector
- 17 Sep 2019 Results presented in the Nordic Nanovector media release.
- 17 Sep 2019 According to a Nordic Nanovector media release, Dr Arne Kolstad will present data from the first safety cohort of three patients of this trial.
- 21 May 2019 According to a Nordic Nanovector media release,data read-out is expected during the second half of 2020.